Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Transcriptional Regulation and Therapeutic Modulation of Muscle CDKN1A in Cancer Cachexia

Award Number: K99CA304466
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 07/09/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

Transcriptional Regulation and Therapeutic Modulation of Muscle CDKN1A in Cancer Cachexia - PROJECT SUMMARY Cancer cachexia is a debilitating syndrome characterized by muscle wasting, weight loss, and metabolic dysfunction, significantly reducing patient quality of life and survival. Affecting up to 80% of advanced cancer patients and responsible for approximately 20% of cancer-related deaths, effective treatments are lacking due to limited understanding of its molecular mechanisms. Elevated levels of cyclin-dependent kinase inhibitor 1A (CDKN1A) in muscle have been identified as a robust prognostic biomarker for cachexia severity and patient survival. Modulation of the transcriptional repressor B-cell lymphoma 6 (BCL6) directly regulates CDKN1A expression via transcriptional repression. Repressing CDKN1A, either through BCL6 overexpression or direct knockdown, ameliorates proinflammatory atrophy and improves metabolic parameters under cachexia conditions. These findings suggest that the BCL6-CDKN1A interaction plays a pivotal role in regulating muscle metabolism and inflammation, presenting a unique opportunity to develop integrated anti-cachexia therapies. This project aims to elucidate the role of muscle CDKN1A in cancer cachexia and develop novel therapeutic strategies targeting the BCL6-CDKN1A pathway to combat muscle wasting. Specifically, the research will: 1. Elucidate the role of muscle CDKN1A in muscle dysfunction during cancer cachexia by utilizing muscle-specific CDKN1A knockout mice to assess impacts on muscle function, body composition, metabolic parameters, and survival outcomes. 2. Define the temporal regulation of CDKN1A by BCL6 in response to nutrient availability by investigating the dynamics of BCL6-mediated repression of CDKN1A and its effects on muscle metabolism during fasting and cancer cachexia. 3. Assess immune modulation of muscle CDKN1A as a therapeutic strategy by dissecting the role of BCL6-mediated CDKN1A repression in muscle inflammation, identifying cancer-specific mechanisms of CDKN1A induction, and evaluating the translational potential of CDKN1A- modulating compounds. The research integrates advanced genetic tools, transgenic mouse models, next- generation sequencing, and high-throughput clinical compound screening to uncover molecular mechanisms driving muscle wasting in cancer cachexia. By targeting the BCL6-CDKN1A pathway, the project seeks to develop innovative therapies to improve muscle function and quality of life for cancer patients. The candidate's long-term career goal is to establish an independent research laboratory focused on understanding the mechanisms of muscle wasting in cancer cachexia and developing novel therapeutic strategies. The career development plan involves interdisciplinary training under the mentorship of Dr. Ronald Evans at the Salk Institute, an exceptional environment for research on tissue crosstalk and molecular endocrinology. The candidate will acquire expertise in advanced research tools, leadership skills, grant writing, and manuscript preparation, facilitating the transition to an independent investigator capable of leading a research team and securing funding.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $130,501 )
2026	2026	SALK INSTITUTE FOR BIOLOGICAL STUDIES, SAN DIEGO, CALIFORNIA, THE	10010 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Research Manpower	000	2	8/3/2026	NON-COMPETING CONTINUATION	$130,501
														Subtotal = $130,501

Issue Date FY: 2025 ( Subtotal = $130,501 )
2025	2025	SALK INSTITUTE FOR BIOLOGICAL STUDIES, SAN DIEGO, CALIFORNIA, THE	10010 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Research Manpower	000	1	7/9/2025	NEW	$130,501
														Subtotal = $130,501

Grand Total All Awards = $261,002

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Transcriptional Regulation and Therapeutic Modulation of Muscle CDKN1A in Cancer Cachexia

Award Number: K99CA304466

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 07/09/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer